Core Viewpoint - Vor Biopharma Inc. has initiated a public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million, aimed at advancing its clinical-stage biotechnology efforts in treating autoimmune diseases [1][2]. Company Overview - Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, particularly through its lead product, telitacicept, which is in Phase 3 clinical development [5]. Offering Details - The public offering consists of $100 million in common stock, with a 30-day option for underwriters to acquire an additional $15 million [1]. - The offering is subject to market conditions and other factors, with no guarantee on completion or terms [1]. - The shares are being offered under a shelf registration statement effective since March 31, 2025, and will be made available through a prospectus supplement [3].

Core Viewpoint - Alpine Income Property Trust, Inc. has announced a public offering of 2,000,000 shares of its 8.00% Series A Cumulative Redeemable Preferred Stock at a price of $25.00 per share, expecting to raise gross proceeds of $50 million before expenses [1][2]. Group 1: Offering Details - The Series A Preferred Stock will have a liquidation preference of $25.00 per share [1]. - The offering is expected to close on November 12, 2025, subject to customary closing conditions [1]. - Underwriters have an option to purchase an additional 300,000 shares to cover over-allotments [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate and working capital purposes, which may include property acquisitions, commercial loan and investment opportunities, and repayment of debt [2]. Group 3: Listing and Management - The Company intends to file an application to list the Series A Preferred Stock on the New York Stock Exchange under the ticker symbol "PINE-PA" [2]. - Raymond James, Stifel, and Baird are acting as joint book-running managers for the offering, with several other firms as co-managers [2]. Group 4: Company Overview - Alpine Income Property Trust, Inc. is a publicly traded real estate investment trust focused on delivering attractive risk-adjusted returns and dependable cash dividends by investing in single tenant net leased commercial properties [5].

Core Viewpoint - Alpine Income Property Trust, Inc. has announced a public offering of its Series A Cumulative Redeemable Preferred Stock, with a liquidation preference of $25.00 per share, aiming to utilize the net proceeds for general corporate purposes, including property acquisitions and debt repayment [1][5]. Group 1: Offering Details - The Series A Preferred Stock will be listed on the New York Stock Exchange under the ticker symbol "PINE-PA" [2]. - The offering will be conducted under the existing shelf registration statement on Form S-3 filed with the SEC, and will be made via a prospectus supplement [3]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be used for general corporate and working capital purposes, which may include property acquisitions, commercial loan opportunities, and repayment of debt [1]. Group 3: Company Overview - Alpine Income Property Trust, Inc. is a publicly traded real estate investment trust focused on delivering attractive risk-adjusted returns and dependable cash dividends by investing in single tenant net leased commercial properties, primarily leased to high-quality publicly traded and credit-rated tenants [5].

Core Viewpoint - Guardant Health, Inc. has announced an upsized underwritten public offering of its common stock, indicating strong market interest and confidence in its growth potential [1] Group 1: Offering Details - The company is offering 3,333,333 shares of common stock at a public offering price of $90.00 per share [1] - The size of the offering was increased from a previously announced $250.0 million, reflecting a positive adjustment based on demand [1] Group 2: Market Implications - The upsizing of the offering suggests robust investor interest in Guardant Health's stock, which may enhance its capital position for future growth initiatives [1]

Core Viewpoint - Flux Power Holdings, Inc. has announced a public offering of 3,840,000 shares at a price of $2.50 per share, aiming to raise approximately $9.6 million before expenses [1]. Group 1: Offering Details - The public offering consists of 3,840,000 shares priced at $2.50 each, with an additional option for the underwriter to purchase up to 576,000 shares [1]. - The gross proceeds from the offering are expected to be around $9.6 million, excluding any additional shares purchased by the underwriter [1]. - The offering is set to close on November 3, 2025, pending customary closing conditions [1]. Group 2: Underwriter Information - Lake Street Capital Markets, LLC is serving as the sole book-running manager for the offering [2]. Group 3: Regulatory Compliance - A registration statement for the shares has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on October 29, 2025 [3]. - The offering is being conducted solely through a prospectus, with a preliminary prospectus already filed with the SEC [3]. Group 4: Company Overview - Flux Power designs, manufactures, and sells advanced lithium-ion energy storage solutions for various industrial and commercial applications [5]. - The company's products, including lithium-ion battery packs and proprietary battery management systems, offer a more efficient and environmentally friendly alternative to traditional lead-acid and propane solutions [5]. - Flux Power's solutions contribute to reduced CO2 emissions and improved sustainability metrics for fleets [5].

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. has announced a public offering of approximately $75 million, consisting of 4,744,231 shares of common stock priced at $13.00 per share and pre-funded warrants for 1,025,000 shares priced at $12.9999 each, with the offering expected to close on or about November 3, 2025 [1][2]. Group 1: Offering Details - The total public offering size is approximately $75 million before deducting underwriting discounts and estimated offering expenses [1]. - The exercise price of the pre-funded warrants is set at $0.0001 per share [1]. - Corbus has granted underwriters a 30-day option to purchase up to an additional 865,384 shares on the same terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the clinical development of Corbus' pipeline, as well as for working capital and other general corporate purposes [2]. Group 3: Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [5]. - The company's pipeline includes CRB-701, CRB-601, and CRB-913, targeting cancer and obesity treatments [5].

Core Viewpoint - NexMetals Mining Corp. has increased the size of its public offering from C$65 million to C$80 million due to strong demand from institutional investors, marking the second upsizing of the offering [1][3]. Offering Details - The offering will consist of up to 14,035,100 Units, with no over-allotment option available [3]. - Agents will receive a cash fee of 6% of the gross proceeds, with a reduced fee of 2% for sales to certain individuals on a "president's list" for gross proceeds up to C$7 million [3]. - Each Unit will include one common share and one common share purchase warrant, allowing the holder to acquire one common share at a price of C$8.00 for 24 months following issuance [3]. Use of Proceeds - The net proceeds from the offering are intended for the prepayment of the first contingent milestone payment under the Asset Purchase Agreement for the Selebi and Selkirk mines, exploration and development activities in Botswana, and general corporate purposes [4]. Closing Timeline - The offering is expected to close on or about November 13, 2025, pending necessary approvals [5]. Company Overview - NexMetals Mining Corp. focuses on the redevelopment of previously producing copper, nickel, and cobalt resources in Botswana [7]. - The company's team has extensive experience in mine discovery and development, with senior members averaging over 20 years in the industry [9].

Core Points - Veru Inc. announced a public offering of 1,400,000 shares of common stock, pre-funded warrants for 7,000,000 shares, and Series A and B warrants for 8,400,000 shares each, with a combined offering price of $3.00 per share [1][2] - The gross proceeds from the offering are expected to be approximately $25.2 million, with potential additional proceeds of about $50.4 million if all warrants are exercised [2] - The net proceeds will primarily fund the development of enobosarm, particularly for the Phase 2b PLATEAU clinical study, and will also cover working capital and general corporate purposes [3] Offering Details - The offering includes common stock, pre-funded warrants, and Series A and B warrants, all sold by Veru under a previously filed shelf registration statement [4] - The offering is expected to close on or about October 31, 2025, pending customary closing conditions [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on innovative medicines for cardiometabolic and inflammatory diseases [6]

Core Viewpoint - Cleveland-Cliffs Inc. has announced a public offering of 75,000,000 common shares, aiming for gross proceeds of approximately $964 million before discounts and expenses, with a potential additional 11,250,000 shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is expected to close on October 31, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will primarily be used to repay borrowings under the company's asset-based credit facility, with any remaining funds allocated for general corporate purposes [2]. - UBS Securities LLC is acting as the underwriter for the offering, which will be available for sale on the New York Stock Exchange and other markets at prevailing market prices [3]. Group 2: Company Overview - Cleveland-Cliffs is a leading North American steel producer, focusing on value-added sheet products, particularly for the automotive industry [6]. - The company is vertically integrated, covering the entire process from iron ore mining to steelmaking and downstream processing [6]. - Headquartered in Cleveland, Ohio, Cleveland-Cliffs employs approximately 30,000 people across its operations in the United States and Canada [6].

Core Viewpoint - VSE Corporation has priced its public offering of common stock, aiming to raise approximately $384 million to fund its acquisition of Aero 3 and support future strategic acquisitions [1][2]. Group 1: Offering Details - VSE Corporation is offering 2,352,941 shares of common stock at a price of $170.00 per share [1]. - The underwriters have a 30-day option to purchase an additional 352,941 shares [1]. - The offering is expected to close on October 29, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be approximately $384 million after deducting underwriting discounts and commissions [2]. - VSE intends to use the proceeds to fund the cash consideration for the acquisition of Aero 3, support potential future strategic acquisitions, and for general corporate purposes [2]. Group 3: Underwriters - Jefferies and Morgan Stanley are acting as joint lead book-running managers for the offering [3]. - RBC Capital Markets and William Blair are serving as joint book-runners, while Truist Securities, B. Riley Securities, and Stifel are additional book-runners [3]. - KeyBanc Capital Markets, Benchmark, a StoneX Company, and Jones are co-managers for the offering [3]. Group 4: Company Overview - VSE Corporation is a leading provider of aviation aftermarket distribution and repair services, focused on enhancing the productivity and longevity of high-value assets [6]. - The company is headquartered in Miramar, Florida, and supports engine component and airframe accessory part distribution and repair services for commercial and business aviation operators [6].